Advertisement
ORTX Novinky na Forexu
Orchard Therapeutics Gets Swissmedic Approval For Libmeldy In Early-onset MLD
Gene therapy leader Orchard Therapeutics plc (ORTX) announced Monday the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, for the treatment of early-onset metachromatic leukodystrophy (MLD).
RTTNews
|
Před 517 dny
Orchard Therapeutics Says FDA Accepts BLA For OTL-200 In Metachromatic Leukodystrophy
Orchard Therapeutics (ORTX), a global gene therapy leader, announced Monday that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for OTL-200 in metachromatic leukodystrophy (MLD) under Priority Review.
RTTNews
|
Před 601 dny
